

GLAXOSMITHKLINE PLC
Form 6-K
April 01, 2009

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending April 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 31 March 2009, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary shares at a price of £10.55 per Ordinary share and \$30.21 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2009 to 31 March 2009

:

Non Executive Director	Ordinary Shares	American Depository Shares (ADSs)
Sir Christopher Gent	3,199.05	
Prof Sir Roy Anderson	799.76	
Dr Stephanie Burns		618.11
Mr Lawrence Culp		1,236.22
Sir Crispin Davis	2,488.150	
Sir Deryck Maughan		1,236.22
Dr Daniel Podolsky		865.36
Sir Ian Prosser	1,599.53	
Dr Ronaldo Schmitz	995.26	
Mr Tom de Swaan	799.76	
Sir Robert Wilson	740.52	

The Company and the Non-Executive Directors were informed of these allocations on 1 April 2009.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell
Company Secretary
1 April 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 01, 2009

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc